Activity of daptomycin against Gram-positive bacterial isolates from Indian medical centres (2006-2007)

International Journal of Antimicrobial Agents

Volumn 34, Issue 5, 2009, Pages 497-499

  Mathai, Dilip ^a   Biedenbach, Douglas J ^b   Jones, Ronald N ^b   Bell, Jan M ^c   Turnidge, John ^c,d   Sader, Helio S ^b  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b JMI LABORATORIES   (United States)

^c WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; OXACILLIN; SULFAMETHOXAZOLE; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG POTENCY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS GALLINARUM; GRAM POSITIVE BACTERIUM; INDIA; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACADEMIC MEDICAL CENTERS; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INDIA; MICROBIAL SENSITIVITY TESTS;

EID: 69949166206     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.06.008     Document Type: Letter

References (7)

1. Rosenthal V.D., Maki D.G., Mehta A., Alvarez-Moreno C., Leblebicioglu H., Higuera F., et al. International Nosocomial Infection Control Consortium Members. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 36 (2008) 627-637
2. Ghoshal U., Garg A., Tiwari D.P., and Ayyagari A. Emerging vancomycin resistance in enterococci in India. Indian J Pathol Microbiol 49 (2006) 620-622
3. Levine D.P. Clinical experience with daptomycin: bacteraemia and endocarditis. J Antimicrob Chemother 62 Suppl. 3 (2008) iii35-iii39
4. Leonard S.N., and Rybak M.J. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. J Antimicrob Chemother 63 (2009) 155-160
5. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M07-A7. Wayne, PA: CLSI; 2006.
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009.
7. Biedenbach D.J., Bell J.M., Sader H.S., Fritsche T.R., Jones R.N., and Turnidge J.D. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Int J Antimicrob Agents 30 (2007) 143-149